Amgen-Astrazeneca Tezpire available in U.S. for severe asthma

 Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S. TEZSPIRE was approved by the U.S. Food and Drug Administration (FDA) on Dec. 17, 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.1

https://finance.yahoo.com/news/tezspire-tezepelumab-ekko-now-available-120000189.html